Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery

  • days left to enroll
  • participants needed
  • sponsor
    University Hospital, Strasbourg, France
Updated on 15 December 2021
growth hormone


At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control. Discontinuation of treatment is therefore most often decided by the practitioner, on the basis of his experience and knowledge of the patient, the long-term course with somatostatin analogues being very little described.

Thus, although hormonal control is achieved in a majority of cases under medical treatment, we do not know if it is possible to stop treatment and in this case how the pathology evolves. It would appear that approximately 40% of patients defined as very good responders to somatostatin analogues may gradually space their injections.

Condition Acromegaly
Clinical Study IdentifierNCT05149495
SponsorUniversity Hospital, Strasbourg, France
Last Modified on15 December 2021


Yes No Not Sure

Inclusion Criteria

Major subject (≥18 years old)
Having been seen at least once in consultation in the Internal Medicine, Endocrinology and Nutrition department of Hautepierre Hospital
Subject operated for a pituitary adenoma at the HUS between 01/01/2000 to 09/01/2021
In whom biological confirmation of recurrence has been demonstrated
Patient not having expressed his opposition, after information, to the reuse of his data for scientific research purposes

Exclusion Criteria

Subject having expressed opposition to participating in the study
Treatment pre and / or post surgery by radiotherapy
No recurrence
No treatment with a somatostatin analogue for recurrence
Subject under guardianship, curatorship or safeguard of justice
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note